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Objective: To investigate the contribution of MYH associated
polyposis coli (MAP) among polyposis families in the
Netherlands, and the prevalence of colonic and extracolonic
manifestations in MAP patients.
Methods: 170 patients with polyposis coli, who previously
tested negative for APC mutations, were screened by
denaturing gradient gel electrophoresis and direct sequen-
cing to identify MYH germline mutations.
Results: Homozygous and compound heterozygous MYH
mutations were identified in 40 patients (24%). No difference
was found in the percentage of biallelic mutation carriers
between patients with 10–99 polyps or 100–1000 polyps
(29% in both groups). Colorectal cancer was found in 26 of
the 40 patients with MAP (65%) within the age range 21 to
67 years (median 45). Complete endoscopic reports were
available for 16 MAP patients and revealed five cases with
gastro-duodenal polyps (31%), one of whom also presented
with a duodenal carcinoma. Breast cancer occurred in 18%
of female MAP patients, significantly more than expected
from national statistics (standardised morbidity ratio = 3.75).
Conclusions: Polyp numbers in MAP patients were equally
associated with the attenuated and classical polyposis coli
phenotypes. Two thirds of the MAP patients had colorectal
cancer, 95% of whom were older than 35 years, and one
third of a subset of patients had upper gastrointestinal
lesions. Endoscopic screening of the whole intestine should
be carried out every two years for all MAP patients, starting
from age 25–30 years. The frequent occurrence of additional
extraintestinal manifestations, such as breast cancer among
female MAP patients, should be thoroughly investigated.
M
AP (MYH associated polyposis) is an autosomal
recessive disease characterised by the development
of multiple adenomatous polyps and, eventually,
colorectal cancer (CRC).1 Carriers are homozygous or
compound heterozygous for germline mutations in the
mutY human homologue (MYH) gene, located on chromo-
some 1 between p32.1 and p34.3.2 The MYH protein is a base
excision repair (BER) glycosylase that is involved in the
repair of DNA damage caused by the oxidation of a guanine
leading to 8-oxo-7,8-dihydroguanine (8-oxoG).3 In the
process of replication it excises the adenine mispaired
opposite the oxo-G. When the MYH protein is dysfunctional,
G:CRT:A mutations can occur in genes such as APC and
KRAS.1 4
Since the report by Al Tassan et al of germline biallelic MYH
mutations in polyposis patients,1 several clinical studies have
provided additional insight into the clinical features of
MAP.5–8 The highest percentage (29%) of homozygous and
compound heterozygous MYH mutations was found in
patients with 15 to 100 adenomas.5 In two series—with,
respectively, 107 and 38 patients with classical FAP but
without the APC mutation—biallelic MYH mutations were
identified in 7% and 13% of the cases.5 8 Accordingly, the
majority of MAP cases were characterised by polyp counts in
the range from 10 to 100. So far, six ‘‘CRC only’’ patients and
one with more than 1000 polyps who carry biallelic MYH
mutations have been described.9–11
Approximately 50% of the MAP patients develop CRC.5 8 10
A few extracolonic manifestations—including duodenal
adenomas (n=3), osteoma (n=2), congenital hypertrophy
of the retinal pigment epithelium (CHRPE) (n=4), and
dental cysts (n=1)5 7 8—have been observed in MAP
patients. In addition, one case of stomach cancer was
reported in a 17 year old patient.7
It is likely that other reports focused mainly on the
occurrence of colonic lesions. In this study we investigated
the contribution of MAP among polyposis families in the
Netherlands, and the prevalence of both colonic and
extracolonic manifestations in MAP patients.
METHODS
We selected 170 index patients from all the patients with
polyps referred for APC germline mutation analysis to the
DNA Diagnostic Laboratory of Human and Clinical Genetics
in Leiden from 1986 to 2002. Patients were recruited from
throughout the Netherlands, the vast majority being of white
northern European origin. We excluded those with a
pathogenic APC or mismatch repair gene germline mutations,
inadequate clinical data, or insufficient DNA quality for MYH
mutation analysis. We did not exclude two patients with the
low penetrant I1307K mutation in the APC gene.12 Informed
consent was obtained for DNA testing according to protocols
approved by local ethics review boards. Clinical and
pathological data were obtained from patient records to
confirm the diagnosis. The endoscopic reports were studied to
assay the total number of polyps in the colon that the patient
had developed over time (metachronous count). For practical
Abbreviations: AFAP, attenuated familial adenomatous polyposis;
APC, adenomatous polyposis coli; BER, base excision repair; CHRPE,
congenital hypertrophy of the retinal pigment epithelium; CRC,
colorectal cancer; DGGE, denaturing gradient gel electrophoresis; FAP,
familial adenomatous polyposis coli; MAP, MYH associated polyposis;
MSI, microsatellite instability; SMR, standardised morbidity ratio
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reasons, the index patients were divided into four categories:
less than 10 adenomas; between 10 and 100 adenomas;
between 100 and 1000 adenomas; and more than 1000
adenomas. Unfortunately, the endoscopy and pathology
reports for 29 index patients gave descriptions like ‘‘poly-
posis’’ or ‘‘multiple’’ rather than the exact number of
adenomas.
MYH mutation analysis
Polymerase chain reaction and denaturing gradient
gel electrophoresis
All DNA amplifications were carried out in a 25 ml volume
containing 45 mM Tris HCl, pH 8.3, 11 mM (NH4)2SO4,
45 mM MgCl2, 0.2 mM of each dNTP, 110 mg/ml bovine
serum albumin (BSA), 4 mM EDTA, 10% glycerol, 10 pmol of
each primer, and 1 U polymerase and were subjected to 35
polymerase chain reaction (PCR) cycles (30 seconds at 94 C˚,
30 seconds at 55 C˚ or 58 C˚, and 60 seconds at 72 C˚).
Oligonucleotide sequences (table 1) were designed from
intron–exon boundaries of the MYH gene using the DNA20
computer program (designed by HT Huisman, University of
Groningen). For exons 2, 7, 8, and 10, DGGE analysis was
undertaken and a 55 base pair (bp) GC clamp was present at
the 59 of the forward oligonucleotide. Denaturing gradient gel
electrophoresis (DGGE) analysis was carried out as described
by Fodde et al.13
Direct sequence analysis
The PCR for the sequence analysis was carried out with
oligonucleotide primers specific for the 16 coding exons of
the MYH gene, extended with an M13 forward or reverse
sequence. Some exons were combined into one fragment
(table 1), and in all nine fragments covered the 16 coding
exons of the MYH gene. The primer sequences are given in
table 1. PCR products were sequenced on an ABI 3730 DNA
analyser (Applied Biosystems, Foster City, California, USA)
using their BigDye Terminator cycle sequencing ready
reaction kit. The raw sequence data were analysed using
SeqScape software for comparative sequence analysis
(Applied Biosystems). Detected mutations were confirmed
on a second, independent DNA sample when available.
Nucleotide numbering of the MYH gene was based on the
sequence of the NCBI website (http://www.ncbi.nlm.nih.gov/,
accession number NT_004852.14), changed according to
published reports,1 with base 1 corresponding to the first
base of the initiation codon, and the first 11 codons of exon 3
considered as non-coding). Splice prediction was carried out
with Fruitfly and SpliceSiteFinder software, available from
Table 1 Primer sets for MYH gene mutation analysis
Exon Purpose Oligonucleotide sequence (59-39)
1 Sequence cggtgtacaacggaacttgt
gacgtctgaacggaagttcg
2 Sequence ccttggaaggcctcaaaat
cctgaatctgcctttcatgg
2 DGGE gccgcctgcagcccgcgccccccgtgcccccgccccgcccccggcccgggcgccggtggatgagagggagatagc
gggcggggcgaatgagccttgggccacaac
3-4-5 Sequence atactgccacaggctgct
ctctcatctggggtctga
6-7-8 Sequence ttggggtgggtgtagagaag
agaggggccaaagagttagc
7 DGGE gccgcctgcagcccgcgccccccgtgcccccgccccgcccccggcccgggcgccgagggtaggggaaataggaac
gggcggggcgtataagacacccaagactcc
8 DGGE gccgcctgcagcccgcgccccccgtgcccccgccccgcccccggcccgggcgccgggtaaggggatggcaggagg
ggctgggaggaaggaggctg
9-10-11 Sequence gtgcccagcctccttcct
agaactggaatggggcttct
10 DGGE gccgcctgcagcccgcgccccccgtgcccccgccccgcccccggcccgggcgccgggtgcttcaggggtgtctgc
gggcggggcgcttctcactgccccttcccc
12-13 Sequence tctaggttggcccctaaagc
aagggtcaaggggttcaaat
14 Sequence cggaatagccaaggatgttg
ttcatgtagaacatgtaggaaacac
15 Sequence tgaagttaagggcagaacacc
actgatggctccacaattca
16 Sequence gggaaagggagagaggacaa
caaaaataagcactttactaacaacag
Table 2 Results of MYH mutation analysis in relation to cumulative polyp counts among
170 patients (metachronous)
Number of
polyps
Number of
patients
Biallelic
carriers
Monoallelic
carriers
Age at diagnosis
(mean), years
1–9 33 0 1 (1 UV) 22–73 (47)
10–99 83 24 (29%) 3 (1 UV) 12–76 (46)
100–1000 24 7 (29%) 1 12–67 (41)
.1000 1 0 0 48
Polyposis 17 7 (41%) 0 21–59 (41)
Multiple 10 2 (20%) 1 16–64 (46)
Unknown* 2 0 0
Total 170 40 (24%) 6 (2 UV) (3.5%) 12–76 (45)
*Number of polyps not defined.
UV, unclassified variant.
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the internet: http://www.fruitfly.org/seq_tools/splice.html,
http://www.genet.sickkids.on.ca/,ali/splicesitefinder.html.
Southern blot analysis of MYH was carried out for 95 of the
170 index patients and was done mainly as previously
described.14 We used HindIII and BglII digests, followed by
hybridisation with two cDNA probes encompassing exons 1–
10 (MYH 59) and exons 10–16 (MYH 39), respectively.
Statistics
Differences in percentages were assessed by the x2 test. The F
test was used for comparing age of diagnosis and percentages
in more than two groups. A probability (p) value of ,0.05
was considered as statistically significant. All tests were
carried out with SPSS 11.01 (SPSS, Chicago, Illinois, USA).
We calculated the expected number of breast cancer cases
using rates for each five year calendar period and age group
from the Dutch Cancer Registry.15 SMR-exact was used to
calculate the significance and (Poisson) confidence interval
for the standardised morbidity ratio (SMR)—that is, the ratio
between observed and predicted morbidity of breast cancer
among the female MYH patients compared with breast
cancer in the Dutch population (http://home.clara.net/sisa/
smrhlp.htm).
RESULTS
MYH mutation analysis
Of the 170 index patients analysed, 40 (24%) were found to
carry (presumed) homozygous or compound heterozygous
MYH germline mutations (table 2). In addition, we identified
six carriers of a heterozygous mutation (3.5%)—four patho-
genic mutations and two unclassified variants. Two index
patients with biallelic MYH mutations had consanguineous
parents (table 3). Southern blot analysis in 95 patients did
not reveal any gross genomic rearrangements of the MYH
gene. One novel missense change, P391L, was found in 14%
of the patients with biallelic mutations. Two other novel
nonsense mutations, Q377X and R233X, were found: the first
in a homozygous patient of Turkish origin, and the second in
a patient who was compound heterozygote for R233X and
Y165C. We also identified one novel, c649-1GRA (IVS8) and
one previously reported splice site mutation, c891+3ARC
(IVS10), affecting the wild type splice acceptor and splice
donor recognition sites of exons 8 and 10, respectively. Two
further unclassified variants were found in patients where no
additional MYH variant could be identified: D91N in exon 3,
and P366T in exon 13, within a stretch of evolutionarily
conserved and non-conserved residues, respectively. The
pathogenicity of both substitutions is unclear from the
evidence available.
Colorectal polyp multiplicity and cancer risk in MAP
Equal frequencies of biallelic MYH germline mutations were
observed in patients with 10–99 (29%) and 100–1000
adenomas (29%) (table 2). No biallelic mutations were found
in patients with 1–9 polyps or in a patient with more than
1000 polyps.
The mean age at diagnosis of MAP patients was 45 years,
ranging between 21 and 67 (median, 45). In most MAP
patients, the adenomatous polyps were distributed through-
out the colon.
Of the 40 patients with homozygous or compound
heterozygous MYH mutations, 26 (65%) were diagnosed with
CRC, in 130 patients without biallelic MYH mutations the
percentage of CRC patients was 45% (59/130). In MAP
patientsx CRC was found at first endoscopy in a majority of
cases (24 of 26). Sixteen of the 26 CRC cases (62%) were right
sided (that is, proximal to the splenic flexure). Two patients
presented with two and one patient with five synchronous
carcinomas (patients 9, 35, and 11, respectively). A second
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(metachronous) CRC was identified during follow up in two
other patients, while a third patient developed three adeno-
carcinomas in the colon and a carcinoid tumour in the ileum
metachronously (patients 7, 18, and 12, respectively, table 3).
In all, 37 CRCs were found in 26 patients. The Dukes classi-
fication was variable: seven of the 26 cases were stage D (27%),
five of which were right sided. Microsatellite instability (MSI)
was analysed in CRCs from 16 index patients and all the 16
tumours tested showed stable microsatellites. The median age
of onset of CRC in our series is 45 years, ranging from 21 to 67.
Figure 1 shows the distribution of age of onset of CRC in MAP
patients both in our series and those in published reports.
Thirty six patients with biallelic MYH gene mutations
underwent bowel surgery at a mean age of 46 years (ranging
from 21 to 67 years): 12 because of their high polyp counts,
and 24 because of the presence of colorectal carcinoma.
Thirty two patients underwent a total colectomy, carried out
in one or more surgical procedures.
Extracolonic manifestations in MAP
Of 16 MAP patients who underwent upper gastrointestinal
endoscopy, five (31%) showed an FAP associated extra-
colonic manifestation, namely duodenal adenomas in four
cases and gastric fundic gland polyposis in one. Duodenal
carcinoma was diagnosed in one of the four patients with
duodenal adenomas. The duodenal adenomas were diag-
nosed at a mean age of 52 years (range 36 to 65). One patient
was reported to have oesophageal cancer in the presence of a
Barrett’s oesophagus with dysplasia.
Of the 22 female MAP patients, four (18%) have been
diagnosed with breast cancer. The first patient had a
unilateral breast cancer twice, though with different histol-
ogies, diagnosed at age 76 and 78 years old (intracystic
papillary carcinoma in situ and an infiltrating ductal
carcinoma with a minor in situ component; patient 12).
The second patient was diagnosed with breast cancer at age
55 years (ductal carcinoma in situ with a microinvasive
component; patient 34). The third patient had bilateral breast
cancer at age 49 years (pathology unknown; patient 15), and
the fourth patient had breast cancer at age 49 years
(pathology unknown; patient 38) but had also had cervical
carcinoma at age 27 years (squamous cell carcinoma, human
papillomavirus (HPV) status unknown).
Family history
Family history data were available for 167 of the index
patients. In all, 103 index patients had a family history
compatible with an autosomal dominant pattern of inheri-
tance (that is, more than one generation with either polyposis
or CRC), whereas 64 cases suggest recessive inheritance. The
frequency of biallelic MYH mutations in these two groups is
shown in table 4. We were able to obtain family history data
for 39 of the 40 patients with biallelic MYH mutations, and
we identified a total of 164 siblings and 78 parents. Of 92
siblings examined, 29 (32%) were found to have polyps or
colorectal carcinomas. Of 78 parents, five were diagnosed
with CRC, four with polyps, while endoscopies revealed no
abnormalities in six parents.
Table 4 Results of MYH mutation analysis in relation to family history of polyposis
patients
Number of polyps
Sporadic or autosomal recessive* Autosomal dominant
Total Biallelic Total Biallelic
1–9 5 None 27 None
10–99 37 17 (46%) 45 7 (16%)
100–1000 10 3 (30%) 14 4 (29%)
.1000 1 None None None
Polyposis 3 2 (67%) 13 4 (31%)
Multiple 7 2 (29%) 3 None
Unknown 1 None 1 None
Total 64 24 (38%) 103 15 (15%)
For assessing the mode of inheritance, first and second degree relatives were considered as patients if they had>3
adenomas (or 2 at young age, ie, ,40 years) and/or CRC. The family history was considered dominant if patients
occurred in at least two generations, and recessive if patients were siblings. The family history for three index
patients was not available and these three were not included in this table.
*26 patients with a recessive pattern of inheritance and 38 apparently sporadic cases with 9 and 15 biallelic MYH
patients, respectively.
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Figure 1 Age at diagnosis of
homozygous and compound
heterozygous MAP patients with
colorectal carcinoma (CRC). In all, 73
patients are included, 26 from our
series (light bars) and 47 (dark bars)
from other studies.5, 7–9, 24, 25
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DISCUSSION
In this study we describe the largest series of patients with
homozygous and compound heterozygous mutations in the
MYH gene reported so far. We found that in the Dutch
population, MAP polyp counts are equally associated with the
attenuated and florid forms of polyposis coli. This is in sharp
contrast with previous studies in which the yield of the
biallelic MYH mutation carriers was higher in patients with
10–100 polyps than in those with 100–1000 polyps.5 8 As in
these and other studies, we investigated patients who
previously tested negative for the presence of germline APC
mutations. Hence we assume that the actual prevalence of
MYH biallelic mutations among polyposis patients is lower.
Considering that APC mutations are detected in approxi-
mately 60–80% of classical FAP patients and in 10–30% of
attenuated FAP patients,MYHmutations are likely to account
for about 10% and 20–25% of patients in these groups,
respectively.16 17
MYH mutation spectrum
DGGE and direct sequencing identified 40 biallelic germline
MYH gene point mutations in 170 index patients. Apparently,
larger genomic rearrangements do not play an important role
in MAP as Southern blot analysis in a subset of patients did
not reveal any deletions or duplications.
In our series we found a relatively high frequency (14%) of
a previously unreported mutation, P391L in exon 13, which
may suggest a founder mutation. Although haplotype
analysis was not carried out, P391L carriers were found in
different regions of the central and southern parts of the
Netherlands and are apparently unrelated. Population spe-
cific MYH mutations have already been reported in India
(E466X)7 and Italy (c1395_1396delGGA).8
MAP colonic manifestations
CRC was found in 65% of biallelicMYHmutation carriers. The
mean age of onset was 47 years. One case (patient 26)
presented with CRC at age 21 and is the youngest MAP
patient with CRC reported so far. Figure 2 shows that the vast
majority of MAP patients (95%) develop CRC after the age of
35 years. In contrast with the findings of Lipton et al, who
reported 71% (17/24) of the carcinomas being confined to the
left side of the colon,4 we found CRC in our MAP patients was
predominantly right sided (62%). The percentage of Dukes
stage D colorectal cancers found in MAP patients (27%) is
higher than the percentage found in general Dutch CRC
patients (19%).18 The latter observation can partly be
explained by the fact that five of these CRC patients had
not been recognised with polyposis before, and their CRCs
were right sided, which may explain their late symptoms.
Extracolonic manifestations
We found a relatively high percentage (31%) of upper
gastrointestinal tract manifestations in MAP patients who
underwent endoscopy (15). One patient (No 1) was found to
have a duodenal carcinoma. To date, clinical data of
approximately 100 MAP patients have been described and
only three cases of duodenal adenomas without duodenal
carcinoma have been reported.5 7 Unfortunately, the number
of MAP patients who underwent upper gastrointestinal
screening was not reported. As endoscopy of the upper
tract is not routinely carried out in patients with 10–100
polyps, 3% is most likely to represent an underestima-
tion. Among FAP patients, the cumulative incidence of
duodenal adenomas is 90% and 4.5% developed duodenal
carcinomas.19 In attenuated FAP, duodenal adenomas are
seen often and duodenal cancer has been described in a few
cases.20
The percentage of cases of breast cancer found in female
MAP patients was 18% (4/22), of whom two had double
breast cancer (bilateral and unilateral). The SMR for
developing breast cancer for female MAP patients compared
with the Dutch population is significantly higher than 1
(3.75, 95% confidence interval, 1.02 to 9.57; p=0.019).
Unfortunately, the prevalence of double tumours in the
Dutch population is unknown and this factor could not
therefore be included in the calculation. To exclude the
possibility that polyposis patients develop breast cancer for
other reasons, we also calculated the SMR in female
polyposis patients without MYH mutations (n=48). A non-
significant SMR of 0.88 was found (95% confidence interval,
0.11 to 3.16; p=0.4). It is noteworthy that the BRCA1
and BRCA2 tumour suppressor proteins, loss of function of
which predisposes to breast or ovarian cancer, participate
in the base excision repair of 8-oxo-G lesions.21 Accordingly,
loss of BER function owing to biallelic MYH mutations
may underlie the increased breast cancer risk observed
among Dutch MAP patients. Moreover, MYH knock-out
mice that also carry heterozygous APC mutations are more
prone to develop mammary tumours than Apc-heterozygotes
only.22
G382D/G382D
Age 70: tens of ad polyps
and CRC (asc c)
G382D/G382D
Age 58: 1 ad polyp
Age 59: CRC (sigmoid)
Died young
Unknown cause
4
No mutation analysis
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3
3
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G382D/G382D
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2
No mutation analysis
Age 39: 3 ad polyps
2
No mutation analysis
Age 35: 12 ad polyps
No mutation analysis
Age 39: 1 ad polyp
Figure 2 Pseudodominant inheritance pattern in an MAP (MYH associated polyposis coli) pedigree (patient 33). ad, adenomatous; asc, ascending
colon; CRC, colorectal carcinoma.
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MAP family history
As expected, more MAP patients were identified in cases with
a family history compatible with an autosomal recessive
mode of inheritance or apparently sporadic presentation (i.e.
24/64, 38%) than in dominant cases (15/103, 15%)
(p=0.001) (table 4). Given an estimated frequency of
heterozygotes in the population of 1–2%,1 9 10 pseudodomi-
nant inheritance of MAP is not uncommon, as illustrated in
patient 33’s pedigree (fig 2). Polyps or CRC were found in
32% of the siblings screened, which is again in agreement
with an autosomal recessive mode of transmission.
Genotype–phenotype correlations
In E coli it has been found that the corresponding mutation of
Y165C (Y82D) has a more deleterious effect on the rate of
adenine removal than the corresponding mutation of G382D
(G253D).1 In addition, heterozygous Y165C mutation carriers
are associated with a higher risk for CRC than G382D
heterozygotes.9 In this study, we detected a non-significantly
earlier age of onset of colorectal polyps in patients homo-
zygous for MYH Y165C compared with G382D and all other
biallelic carriers (data not shown). Combining our data with
93 MAP patients reported worldwide, age at diagnosis of
homozygous Y165C mutation carriers was on average five
years earlier than all other biallelic mutation carriers
(p=0.011; 95% confidence interval, 1.1 to 8.8).5 7 8 10 11 23
However, there was no significant difference in age of onset
between homozygotes for Y165C and G382D. We found no
other significant differences among the three groups relative
to polyp multiplicities or CRC risk.
Conclusions
We show that patients with a polyp count compatible with
either the classical or attenuated form of polyposis coli should
be screened for the presence of MYH mutations. As the vast
majority of MAP patients presents with CRC from the age of
35 years and there is a relatively high prevalence of lesions of
the upper gastrointestinal tract, we recommend endoscopic
screening of the lower and upper gastrointestinal tracts every
two years for MAP patients from 25 to 30 years of age.
Limited numbers of colonic adenomas may initially be
treated by polypectomy, but in patients with large numbers
of polyps a subtotal colectomy is indicated. The relatively
high prevalence of breast cancer warrants further exploration
of the involvement of MYH in breast cancer.
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